The global prevalence of nonalcoholic fatty liver disease (NAFLD) or metabolic associated
fatty liver disease (MAFLD), as it is now known, has gradually increased. NAFLD is a …

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among
reproductive-age women. Patients with non-alcoholic fatty liver disease (NAFLD) often suffer …

Alterations in apoptosis, as reflected by circulating Cytokeratin 18 (CK18), are involved in
the progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis …

Non-alcoholic fatty liver disease (NAFLD) shows liver fat depots without alcohol
consumption. NAFLD does not have specific drug therapies, with a healthy lifestyle and …

Background Non-alcoholic fatty liver disease (NAFLD) is a common liver disease increasing
cardiovascular disease (CVD) morbidity and mortality. Autoantibodies against …

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common chronic
liver disease worldwide–with an estimated global prevalence of 37%. Different from …

Background and Aims Accumulated studies have reported the key role of circulating fetuin-A
in the development and progression of nonalcoholic fatty liver disease (NAFLD) but the …

Nonalcoholic fatty liver disease (NAFLD) affects 75 to 100 million adults in the United States
and is the leading cause of chronic liver disease worldwide, fueled by the rising epidemic of …

This review summarizes the current state of non-invasive diagnosis of non-alcoholic fatty
liver disease (NAFLD). This begins with a brief discussion of blood-based analysis (serum …

Background Chronic kidney disease (CKD) has become a major public health issue.
Meanwhile, renal fibrosis caused by diabetic nephropathy can lead to CKD, regardless of …